Researchers from Apogee Therapeutics Inc. and Paragon Therapeutics Inc. have reported the preclinical characterization of APG-333, a half-life extended monoclonal antibody targeting thymic stromal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback